Efficacy through experience

KOGENATE® Bayer consistently achieves haemostatic control within two infusions1,2 with a high parent‑ and physician‑reported treatment
success rate.

  • In a two‑year post‑marketing observational study, 98.6% of treatment responses were considered very good or good2
  • In a two‑year prospective international clinical study, 90.9% of all treatments with KOGENATE® Bayer were considered excellent or good1

Subjective rating of response to treatment of bleeding episodes1

Subjective rating of response to treatment of bleeding episodes

Adapted from Thromb Haemost, Kreuz W et al.

Categorical responses were “excellent”, “good” (EU)/ “adequate” (NA), “moderate” (EU)/”partial” (NA), or “none”. Subjective assessment of response to treatment was made by the parent or other adult. Responses were “Not Assessable” or “Not Specified” for 32 bleeding episodes in EU and was most often reported for patients on prophylaxis therapy. The subjective rating of response relative to the number of bleeding episodes (EU, n=674; NA, n=504; total, n=1,178) is displayed as a percent above each bar.

Previously treated patients (PTPs)

In an open‑label study of 71 PTPs with severe haemophilia A:

  • 80% of bleeds were treated effectively with a single infusion of KOGENATE® Bayer (n=2585 bleeds)3
  • 93% of bleeds were treated effectively with one or two infusions of KOGENATE® Bayer (n=2585 bleeds)3

Bleed control in PTPs from prospective studies

FVIII
concentrated
Study
duration
Number
of PTPs
Number
of bleeds
Bleeds
controlled
with one
infusion (%)
Bleeds
controlled with
one or two
infusions (%)
KOGENATE®
Bayer3
18 months
to 24 months
71 2585 80 93.5
ReFacto
AF®4
12 months 204 677 74* 88
Advate®5 75 exposure
days
111 510 81 93

Data from non‑comparative studies.

*In study 1, 74% of bleeds were controlled with one infusion. In study 2 the majority of first infusions administered for haemorrhage treatment were rated excellent/good. [413 of 482, 86% (eight not reported)]

Previously untreated patients (PUPs)

In PUPs aged ≤4 years with severe haemophilia A:

  • 74% of all treated bleeding episodes were successfully treated with one infusion of KOGENATE® Bayer (n=1178 bleeds)1
  • 89% of all treated bleeding episodes were successfully treated with one or two infusions of KOGENATE® Bayer (n=1178 bleeds)1

Treatment of bleeding episodes1

Subjective rating of response to treatment of bleeding episodes

Adapted from Thromb Haemost, Kreuz W et al.

References:

  1. Kreuz W et al. Thromb Haemost 2005;93(3):457-467.
  2. Musso R et al. Thromb Haemost 2008;99(1):52-58.
  3. Abshire T et al. Thromb Haemost 2000;83:811-816.
  4. Recht M et al. Haemophilia 2009;15(4):869-880.
  5. Tarantino M et al. Haemophilia 2004;10(5):428-437.